LON:AZN

AstraZeneca - AZN Share Forecast, Price & News

GBX 9,933

-83.00 (-0.83%)

(As of 09/26/2022 12:00 AM ET)

Add

Compare

Today's Range: 9,862
▼
£102.23
50-Day Range: 9,933
▼
£114.40
52-Week Range: 8,090.32
▼
£115.40

Volume: 4.85 million shs
Average Volume: 2.15 million shs
Market Capitalization: £153.91 billion

P/E Ratio: N/A
Dividend Yield: 2.21%
Price Target: £106.85

AstraZeneca MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.89 Rating Score
Upside/Downside: 7.6% Upside
£106.85 Price Target
Short Interest: N/A
Dividend Strength: Weak
Based on Four Factors
Sustainability: -2.35
Upright™ Environmental Score
News Sentiment: 0.37
Based on 7 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.82 out of 5 stars

2.4

Analyst's Opinion

Consensus Rating
AstraZeneca has received a consensus rating of Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of £106.85, AstraZeneca has a forecasted upside of 7.6% from its current price of GBX 9,933.
Amount of Analyst Coverage
AstraZeneca has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

N/A

Short Interest

Short Interest
There is no current short interest data available for AZN.

0.8

Dividend Strength

Dividend Yield
AstraZeneca pays a meaningful dividend of 2.21%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
AstraZeneca does not have a long track record of dividend growth.

4.0

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
AstraZeneca has received a 55.59% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Osimertinib", "Olaparib", "SGLT2 inhibitors", "Durvalumab", "Asthma inhalers", and "Antiplatelet medication" products. See details.
Environmental Sustainability
The Environmental Impact score for AstraZeneca is -2.35.

2.4

News and Social Media Coverage

News Sentiment
AstraZeneca has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.48 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for AstraZeneca this week, compared to 5 articles on an average week.
Search Interest
Only 23 people have searched for AZN on MarketBeat in the last 30 days. This is a decrease of -8% compared to the previous 30 days.
MarketBeat Follows
6 people have added AstraZeneca to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

N/A

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AstraZeneca insiders have not sold or bought any company stock.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of AstraZeneca is -168.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of AstraZeneca is -168.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
AstraZeneca has a PEG Ratio of 1.43. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
AstraZeneca has a P/B Ratio of 4.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About AstraZeneca (LON:AZN) Stock

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Receive AZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

AZN Stock News Headlines

September 23, 2022 | morningstar.com

ADRs End Lower, Alibaba and AstraZeneca Trade Actively - Morningstar

September 22, 2022 | finance.yahoo.com

Astrazeneca (AZN) Stock Moves -0.23%: What You Should Know

September 21, 2022 | finance.yahoo.com

AstraZeneca's Asthma Treatment Scores European Approval - Yahoo Finance

September 21, 2022 | americanbankingnews.com

AstraZeneca (LON:AZN) Stock Rating Reaffirmed by Deutsche Bank Aktiengesellschaft

September 19, 2022 | finance.yahoo.com

AstraZeneca (AZN) Gets CHMP Nod for Evusheld to Treat COVID

September 17, 2022 | americanbankingnews.com

Barclays Reiterates Overweight Rating for AstraZeneca (LON:AZN)

September 17, 2022 | americanbankingnews.com

AstraZeneca (LON:AZN) PT Set at GBX 9,800 by Jefferies Financial Group

September 17, 2022 | americanbankingnews.com

AstraZeneca (LON:AZN) Downgraded to Neutral at Credit Suisse Group

September 16, 2022 | barrons.com

EU Backs AstraZeneca Drug For Covid Treatment - Barron's

September 12, 2022 | reuters.com

AstraZeneca beats U.S. shareholder lawsuit over COVID vaccine disclosures - Reuters

September 8, 2022 | finance.yahoo.com

Got $5,000? These 2 Stocks Are No-Brainer Buys.

September 8, 2022 | benzinga.com

Astrazeneca Plc (AZN), (COUP) – Thinking about trading options or stock in Twitter, Coupa Software, Astra - Benzinga

August 31, 2022 | realmoney.thestreet.com

AstraZeneca Looks Vulnerable - RealMoney - RealMoney

August 29, 2022 | 247wallst.com

Monday’s Top Analyst Upgrades and Downgrades: Affirm, AstraZeneca, Broadcom, Dell, Dollar General, Marvell, Tesla, Union Pacific, Workday and More - 24/7 Wall St.

August 27, 2022 | uk.finance.yahoo.com

AstraZeneca's Farxiga cuts death risk in heart failure patients -study - Yahoo Finance UK

August 25, 2022 | marketwatch.com

AstraZeneca's Ultomiris, Tagrisso Treatments Approved in Japan - MarketWatch

August 25, 2022 | marketwatch.com

AstraZeneca Says Lynparza Approved in Japan for Early Breast Cancer - MarketWatch

August 24, 2022 | finance.yahoo.com

AstraZeneca aims to transform cancer outcomes with new data across industry-leading portfolio at ESMO 2022 - Yahoo Finance

August 15, 2022 | morningstar.com

FTSE 100 Rises as AstraZeneca Gains on Positive Trial Result - Morningstar

August 15, 2022 | morningstar.com

AstraZeneca Tops FTSE 100 Risers on Drug Progress - Morningstar

August 1, 2022 | nasdaq.com

The Zacks Analyst Blog Highlights GSK, Merck, Pfizer, Sanofi and AstraZeneca - Nasdaq

July 31, 2022 | nasdaq.com

Do These 3 New Moneymakers for AstraZeneca Make It a Buy? - Nasdaq

July 30, 2022 | ft.com

AstraZeneca to double number of countries where US biotech arm sells rare disease drugs - Financial Times

July 30, 2022 | finance.yahoo.com

3 Stocks We Think Could Beat the Market in the Second Half of 2022

July 25, 2022 | marketwatch.com

ADRs End Higher; AstraZeneca, Barclays Trade Actively - MarketWatch

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive AZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

AZN Company Calendar

Ex-Dividend for 9/12 Dividend: 8/11/2022
Dividend Payable: 9/12/2022
Today: 9/26/2022
Next Earnings (Estimated): 11/10/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Drug Manufacturers - Major
Sub-Industry: N/A
Sector: Medical
Current Symbol: LON:AZN
CUSIP: N/A
CIK: N/A
Web: www.astrazeneca.com
Phone: +44-20-73045000
Fax: N/A
Employees: 83,100
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: £106.85
High Stock Price Forecast: £125
Low Stock Price Forecast: GBX 6,950
Forecasted Upside/Downside: +7.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.89
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: 1,491.44
P/E Growth: 1.43
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 87.31
Current Ratio: 0.96
Quick Ratio: 0.67

Sales & Book Value

Annual Sales: £44.04 billion
Price / Sales: 3.49
Cash Flow: GBX 311.02 per share
Price / Cash Flow: 31.94
Book Value: GBX 2,319.70 per share
Price / Book: 4.28

Miscellaneous

Outstanding Shares: 1,549,495,000
Free Float: N/A
Market Cap: £153.91 billion
Optionable: Optionable
Beta: N/A

Key Executives

Mr. Pascal Soriot D.V.M. (Age 63)
M.B.A., CEO & Exec. Director
Comp: $4.75M

Dr. Aradhana Sarin M.D. (Age 47)
CFO & Exec. Director
Comp: $3.51M

Mr. Marc Dunoyer (Age 70)
CEO of Alexion & Chief Strategy Officer
Comp: $1.66M

Ms. Pam P. Cheng (Age 51)
EVP of Operations & Information Technology and Member of External Sustainability Advisory Board

Mr. Chris Sheldon
Head of Investor Relations

Mr. Jeffrey Pott
Chief HR Officer, Gen. Counsel & Member of External Sustainability Advisory Board

Ms. Katarina Ageborg
EVP of Sustainability, Chief Compliance Officer & Member of External Sustainability Advisory Board

Gonzalo Vina
Head of Global Media Relations

Dr. Menelas Pangalos Ph.D. (Age 55)
EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board

Dr. Ruud Dobber Ph.D.
Exec. Vice-Pres of BioPharmaceuticals Bus. Unit

Key Competitors

View All Competitors

AZN Stock - Frequently Asked Questions

Should I buy or sell AstraZeneca stock right now?: 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AZN shares.
View AZN analyst ratings or view top-rated stocks.
What is AstraZeneca's stock price forecast for 2022?: 9 Wall Street research analysts have issued 12-month price objectives for AstraZeneca's stock. Their AZN share price forecasts range from GBX 6,950 to £125. On average, they predict the company's share price to reach £106.85 in the next twelve months. This suggests a possible upside of 5.3% from the stock's current price.
View analysts price targets for AZN or view top-rated stocks among Wall Street analysts.
How have AZN shares performed in 2022?: AstraZeneca's stock was trading at GBX 8,678 at the start of the year. Since then, AZN shares have increased by 16.9% and is now trading at £101.46.
View the best growth stocks for 2022 here.
When is AstraZeneca's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 10th 2022.
View our AZN earnings forecast.
How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?: AstraZeneca declared a dividend on Friday, July 29th. Investors of record on Thursday, August 11th will be paid a dividend of GBX 76.40 per share on Monday, September 12th. This represents a dividend yield of 0.7%. The ex-dividend date is Thursday, August 11th. The official announcement can be accessed at this link.
Read our dividend analysis for AZN.
Is AstraZeneca a good dividend stock?: AstraZeneca (LON:AZN) pays an annual dividend of GBX 2.83 per share and currently has a dividend yield of 2.21%.
Read our dividend analysis for AZN.

What other stocks do shareholders of AstraZeneca own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include GSK (GSK), NVIDIA (NVDA), Gilead Sciences (GILD), Intel (INTC), Vodafone Group Public (VOD), Advanced Micro Devices (AMD), Alibaba Group (BABA), Pfizer (PFE), QUALCOMM (QCOM) and The Hain Celestial Group (HAIN).
What is AstraZeneca's stock symbol?: AstraZeneca trades on the London Stock Exchange (LON) under the ticker symbol "AZN."
How do I buy shares of AstraZeneca?: Shares of AZN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.
What is AstraZeneca's stock price today?: One share of AZN stock can currently be purchased for approximately £101.46.
How much money does AstraZeneca make?: AstraZeneca (LON:AZN) has a market capitalization of £157.21 billion and generates £44.04 billion in revenue each year.
How many employees does AstraZeneca have?: The company employs 83,100 workers across the globe.
How can I contact AstraZeneca?: AstraZeneca's mailing address is 1 Francis Crick Avenue Cambridge Biomedical Campus, CAMBRIDGE, CB2 0AA, United Kingdom. The official website for the company is www.astrazeneca.com. The biopharmaceutical company can be reached via phone at +44-20-73045000.

This page (LON:AZN) was last updated on 9/26/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

AstraZeneca - AZN Share Forecast, Price & News

AstraZeneca MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About AstraZeneca (LON:AZN) Stock

AZN Stock News Headlines

AZN Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

AZN Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™